Ken Fisher's BCRX Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 2.73 M shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $26.02 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Ken Fisher has maintained a strategic position in BCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 1.23 M shares. Largest reduction occurred in Q3 2023, reducing 1.14 M shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +265,686 | Add 10.77% | 2.73 M | $9.52 |
| Q4 2025 | -165,129 | Reduce 6.27% | 2.47 M | $7.80 |
| Q3 2025 | -149,793 | Reduce 5.38% | 2.63 M | $7.59 |
| Q2 2025 | -269,648 | Reduce 8.83% | 2.78 M | $8.96 |
| Q1 2025 | -130,480 | Reduce 4.10% | 3.05 M | $7.50 |
| Q4 2024 | -155,445 | Reduce 4.66% | 3.18 M | $7.52 |
| Q3 2024 | +481,359 | Add 16.85% | 3.34 M | $7.60 |
| Q2 2024 | -27,916 | Reduce 0.97% | 2.86 M | $6.18 |
| Q1 2024 | +50 | Add 0.00% | 2.88 M | $5.08 |
| Q4 2023 | -300,630 | Reduce 9.44% | 2.88 M | $5.99 |
| Q3 2023 | -1.14 M | Reduce 26.35% | 3.19 M | $7.08 |
| Q2 2023 | +31,157 | Add 0.73% | 4.32 M | $7.04 |
| Q1 2023 | -137,718 | Reduce 3.11% | 4.29 M | $8.34 |
| Q4 2022 | -732,731 | Reduce 14.19% | 4.43 M | $11.48 |
| Q3 2022 | -52,984 | Reduce 1.02% | 5.16 M | $12.60 |
| Q2 2022 | +1.23 M | Add 30.85% | 5.22 M | $10.58 |
| Q1 2022 | -110,229 | Reduce 2.69% | 3.99 M | $16.26 |
| Q4 2021 | +1.09 M | Add 36.31% | 4.1 M | $13.85 |
| Q3 2021 | +994,391 | Add 49.44% | 3.01 M | $14.37 |
| Q2 2021 | +2.01 M | New Buy | 2.01 M | $15.81 |
Ken Fisher's BioCryst Pharmaceuticals Investment FAQs
Ken Fisher first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q2 2021, acquiring 2,011,231 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held BioCryst Pharmaceuticals, Inc. (BCRX) for 20 quarters since Q2 2021.
Ken Fisher's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q2 2021, adding 2,011,231 shares worth $31.8 M.
According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 2,733,253 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $26.02 M.
As of the Q1 2026 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 5,216,829 shares, as reported at the end of Q2 2022.